Thermo Fisher Scientific has raised its 2026 earnings outlook. Against this backdrop, the company expects demand to recover, led by its Precure partnership.
The investment case for holding Thermo Fisher Scientific shares assumes that a recovery in the pharmaceutical and biotechnology sectors and broader demand growth for laboratory services will offset such weaknesses as stagnant academic and government funding and pressure in the Chinese market. The recent upward revision to the company’s 2026 earnings outlook supports that premise. In the near term, attention will focus on whether improving orders in bioproduction and clinical research can sustain organic growth.
Externally, tariffs, foreign exchange and policy shifts are putting pressure on margins in the analytical instruments segment, while substantial debt and a change in management are increasing execution risk. The upward revision is boosting confidence, but is not considered sufficient to fully eliminate these constraints.
The joint Precure venture with Mayo Clinic is positioned as an important partnership linking the company’s instruments and reagents to a large-scale multi-omics data project. This could strengthen coordination between the company’s business and the customer segments currently driving the recovery in demand.
The backdrop to analysts’ forecasts includes a plan to reach revenue of $54.8 billion and profit of $10 billion by 2029. Current forecasting models assume revenue growth of approximately 5.8% annually and an increase in profit of about $3 billion from the current $7 billion.